Qyuns Therapeutics Co., Ltd. (2509.HK)

24.100 +0.400 (+1.69%) At close: 03:59PM HKT

Qyuns Therapeutics Co., Ltd.

Building 1
Room 1310 No. 907 Yaocheng Avenue
Taizhou
China
86 523 8027 6311
https://www.qyuns.net

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 331

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Jiwan Qiu	GM, CEO & Chairman of the Board	2.88M	N/A	1972
Mr. Yiliang Wu	Executive Director & Executive Deputy GM of Cellularforce	1.56M	N/A	1982
Mr. Weidong Lin	Deputy GM & Executive Director	1.94M	N/A	1983
Dr. Jianwei Li	Deputy GM & COO	N/A	N/A	1961
Mr. Shenglong Wu	Deputy GM & Chief Business Officer	N/A	N/A	1974
Ms. Min Fang	Deputy General Manager	N/A	N/A	1976
Mr. Yanbao Hu	Board Secretary & Joint Company Secretary	N/A	N/A	1988
Ms. King Yin Tang	Joint Company Secretary	N/A	N/A	1987

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.

Description

Qyuns Therapeutics Co., Ltd., a clinical-stage biotech company, focuses on the research and development of biologic therapies for autoimmune and allergic diseases in the People's Republic of China. The company's lead product candidates include QX002N, an interleukin (IL)-17A inhibitor in Phase III clinical trial for the treatment of ankylosing spondylitis and lupus nephritis; and QX005N, a monoclonal antibody (mAb) blocking IL-4Ra, which has completed Phase II clinical trial, to treat atopic dermatitis, prurigo nodularis, chronic rhinosinusitis with nasal polyps, chronic spontaneous urticaria (CSU), asthma, and chronic obstructive pulmonary disease (COPD). It also develops QX001S, an IL-12/IL-23p40 inhibitor in Phase III clinical trial for the treatment of psoriasis (Ps), and ulcerative colitis/Crohn's disease (CD); QX004N an IL-23p19 inhibitor in Phase II clinical trial to treat Ps and CD; QX006N, an IFNAR1-targeting mAb, which is in Phase Ib clinical trial, for the treatment of systemic lupus erythematosus; and QX008N, a humanized IgG1 mAb targeting thymic stromal lymphopoietin in Phase Ib clinical trial to treat moderate-to-severe asthma and COPD. In addition, the company is developing QX007N targeting IL-33 for the treatment of COPD and asthma; QX013N targeting c-kit to treat CSU; and QX010N, an IL-31R inhibitor for the treatment of pruritus. Further, it researches, develops, and produces pharmaceutical products; and provides technical consultation services. Qyuns Therapeutics Co., Ltd. was incorporated in 2015 and is headquartered in Taizhou, China.

Corporate governance

Qyuns Therapeutics Co., Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.